Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (11): 657-660.

Previous Articles     Next Articles

Determination of Eight Impurities of Rosuvastatin Calcium Tablets by HPLC

CAI Yin, WU Li, MIAO Yan, ZHOU Zhi-liang, ZHU Jin-lian, XIA Xiao-qin   

  1. Runze Pharmaceuticals Suzhou CO., LTD., Jiangsu Suzhou 215126, China
  • Received:2014-01-10 Revised:2018-07-18 Online:2014-11-08 Published:2016-03-02

Abstract: Objective To establish the related substance method of rosuvastatin calcium tablets. Methods Prepared eight impurities of rosuvastatin calcium tablets first, Column: Agilent extend-C18(4.6 mm×250 mm, 5 μm) with mobile phase consisted of 0.05 M sodium dihydrogen phosphate buffer (adjusted to pH 2.0 with phosphoric acid): acetonitrile: methanol=46:20:34 at a flow rate of 0.7 mL·min-1 when the detective wavelength was set at 242 nm, used external standard method to calculate the content of impurities. Results The contents of (3S, 5S)-rosuvastatin calcium, 5-oxo-rosuvastatin and rosuvastatin-5S-lactone are more than others in three batches of rosuvastatin calcium tablets. Conclusion The contents of impurity A, B, C should not be more than 0.5% and impurity D, E, F, G, H should not exceed 0.2%, for each unspecified impurities not more than 0.2% and not more than 1.5% for total.

Key words: rosuvastatin calcium tablet, related substance, (3S, 5S)-rosuvastatin calcium, 5-oxo-rosuvastatin, rosuvastatin-5S-lactone

CLC Number: 

Copyright © Editorial office of Chinese Journal of Pharmacovigilance
Tel: 010-80990708 E-mail: ywjj@cdr-adr.org.cn